Blue Owl Capital Holdings LP
Blue Owl Capital Holdings LP reported 71 US-listed holdings worth $658.0 million in its 13F for the quarter ended 30 June 2026, filed 11 August 2026. Its largest: Space Exploration Techn Corp. Class A Com STK (36.3%), Aktis Oncology Inc. (15.0%) and Cullinan Therapeutics Inc. (4.3%). Against the quarter before, it opened 18 positions, added to 11, trimmed 13 and sold out of 22.
Reported holdings$658.0M+76.8% on Q1 2026
Positions71-4 on Q1 2026
The largest ten79.3%of its reported holdings
Latest 13FQ2 2026filed 11 August 2026
OpenedAdded toHeldTrimmed
The 14 largest of its 71 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +11.9% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Its reported holdingsThe S&P 500
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Opened 18Added 11Held 29Trimmed 13Sold out 22
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 18
- Space Exploration Techn Corp. Class A Com STK SPCX$239.0 million
- Capital One Financial Corp. COF$24.0 million
- Deep Fission Inc. FISN$14.7 million
- Artiva Biotherapeutics Inc. ARTV$8.5 million
- Compass Pathways PLC CMPS$6.4 million
- Viridian Therapeutics, Inc. VRDN$4.8 million
- Cabaletta Bio Inc. CABA$2.2 million
- Chime Financial, Inc. CHYM$1.8 million
and 10 more in the table below
Added to 11
- Dell Technologies Inc. DELL+19,062 shares · +137%
- Sagimet Biosciences Inc. SGMT+926,667 shares · +278%
- Larimar Therapeutics Inc. LRMR+2.0 million shares · +29%
- Oric Pharmaceuticals Inc. ORIC+250,000 shares · +167%
- Compass Therapeutics Inc. CMPX+682,551 shares · +23%
- Lenz Therapeutics Inc. LENZ+250,000 shares · +49%
- Evommune Inc. EVMN+80,000 shares · +80%
- Corvus Pharmaceuticals Inc. CRVS+63,600 shares · +12%
and 3 more in the table below
Trimmed 13
- Maplight Therapeutics Inc. MPLT-276,000 shares · -27%
- Cullinan Therapeutics Inc. CGEM-370,000 shares · -19%
- Ultragenyx Pharmaceutical Inc. RARE-120,000 shares · -40%
- Eledon Pharmaceuticals Inc. ELDN-853,403 shares · -60%
- Aktis Oncology Inc. AKTS-91,129 shares · -3%
- Eyepoint Pharmaceuticals Inc. EYPT-150,000 shares · -16%
- Aquestive Therapeutics Inc. AQST-405,000 shares · -30%
- Context Therapeutics Inc. CNTX-2.2 million shares · -42%
and 5 more in the table below
Sold out of 22
- Engene Holdings Inc. ENGN$30.1 million last quarter
- Compass Pathways PLC$5.1 million last quarter
- Civeo Corp. Cda CVEO$4.8 million last quarter
- Kalvista Pharmaceuticals Inc. KALV$4.3 million last quarter
- Ovid Therapeutics Inc. OVID$4.2 million last quarter
- Pliant Therapeutics Inc. PLRX$3.7 million last quarter
- Larimar Therapeutics Inc.$1.9 million last quarter
- Engene Holdings Inc. ENGNW$1.3 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Space Exploration Techn Corp. Class A Com STK SPCX | 1.4M | $239.0 million | 36.32% | new |
| Aktis Oncology Inc. AKTS | 3.1M | $99.0 million | 15.04% | -91.1K |
| Cullinan Therapeutics Inc. CGEM | 1.5M | $28.0 million | 4.26% | -370.0K |
| Larimar Therapeutics Inc. LRMR | 9.2M | $27.9 million | 4.25% | +2.0M |
| Nuveen Churchill Direct Lend NCDL | 2.1M | $26.6 million | 4.05% | no change |
| Maplight Therapeutics Inc. MPLT | 729.9K | $26.2 million | 3.98% | -276.0K |
| Capital One Financial Corp. COF | 119.8K | $24.0 million | 3.65% | new |
| Blue Owl Capital Corporation OBDC | 2.0M | $22.2 million | 3.38% | no change |
| Deep Fission Inc. FISN | 1.3M | $14.7 million | 2.24% | new |
| Dell Technologies Inc. DELL | 33.0K | $14.2 million | 2.16% | +19.1K |
| Holley Inc. HLLY | 4.4M | $11.2 million | 1.70% | +140.0K |
| Eyepoint Pharmaceuticals Inc. EYPT | 762.6K | $10.9 million | 1.66% | -150.0K |
| Sagimet Biosciences Inc. SGMT | 1.3M | $9.7 million | 1.48% | +926.7K |
| Corvus Pharmaceuticals Inc. CRVS | 608.6K | $9.1 million | 1.38% | +63.6K |
| Artiva Biotherapeutics Inc. ARTV | 874.5K | $8.5 million | 1.29% | new |
| Compass Therapeutics Inc. CMPX | 3.6M | $7.9 million | 1.21% | +682.6K |
| Conduent Inc. CNDT | 5.0M | $7.4 million | 1.12% | no change |
| Rhythm Pharmaceuticals, Inc. RYTM | 61.5K | $6.8 million | 1.04% | no change |
| Compass Pathways PLC CMPS | 450.0K | $6.4 million | 0.97% | new |
| Ultragenyx Pharmaceutical Inc. RARE | 182.6K | $6.1 million | 0.93% | -120.0K |
| Palvella Therapeutics Inc. Ne PVLA | 36.3K | $5.5 million | 0.84% | +5.0K |
| Imagenebio Inc. IMA | 917.7K | $5.4 million | 0.82% | -41.6K |
| Viridian Therapeutics, Inc. VRDN | 260.0K | $4.8 million | 0.73% | new |
| Immix Biopharma Inc. IMMX | 437.6K | $4.5 million | 0.69% | -110.0K |
| Oric Pharmaceuticals Inc. ORIC | 400.0K | $4.3 million | 0.66% | +250.0K |
| Lenz Therapeutics Inc. LENZ | 756.7K | $4.3 million | 0.65% | +250.0K |
| Aquestive Therapeutics Inc. AQST | 942.9K | $3.9 million | 0.60% | -405.0K |
| Starwood Property Trust, Inc. STWD | 196.4K | $3.2 million | 0.49% | +37.8K |
| Evommune Inc. EVMN | 180.0K | $2.4 million | 0.36% | +80.0K |
| Eledon Pharmaceuticals Inc. ELDN | 566.5K | $2.2 million | 0.34% | -853.4K |
| Cabaletta Bio Inc. CABA | 714.7K | $2.2 million | 0.34% | new |
| Chime Financial, Inc. CHYM | 89.9K | $1.8 million | 0.28% | new |
| Context Therapeutics Inc. CNTX | 2.9M | $1.6 million | 0.25% | -2.2M |
| WW Intl Inc. WW | 84.4K | $1.3 million | 0.20% | -11.2K |
| Marker Therapeutics Inc. MRKR | 554.2K | $814,748 | 0.12% | no change |
| Auven Therapeutics Management ADCT | 733.6K | $784,918 | 0.12% | no change |
| Cybin Inc. HELP | 59.9K | $396,012 | 0.06% | new |
| Ftac Emerald Acquisition Cor FLD | 856.6K | $385,484 | 0.06% | no change |
| Niocorp Devs Ltd NIOBW | 268.3K | $380,958 | 0.06% | -51.8K |
| Rezolve Ai Ltd RZLVW | 235.1K | $213,960 | 0.03% | no change |
| Brand Engagement Network Inc. BNAIW | 1.5M | $203,533 | 0.03% | -213.0K |
| Piper Sandler Companies PIPR | 2.4K | $175,642 | 0.03% | no change |
| Engene Therapeutics Inc W Exp 10/31/202 ENGNW | 511.2K | $148,190 | 0.02% | new |
| Celcuity Inc. CELC | 1.2K | $130,670 | 0.02% | new |
| Stablecoinx Inc. USDEW | 250.0K | $102,500 | 0.02% | new |
| Energy Transfer LP ET | 5.3K | $101,833 | 0.02% | no change |
| Caris Life Sciences, Inc. CAI | 4.7K | $83,950 | 0.01% | no change |
| Vodafone Group Public Limited Company VOD | 5.4K | $71,005 | 0.01% | new |
| Dave Inc. DAVEW | 28.8K | $68,425 | 0.01% | no change |
| Murano Global Invts PLC MRNO | 261.9K | $62,850 | 0.01% | new |
| Alpha Modus Hldgs Inc. AMODW | 1.9M | $55,640 | 0.01% | no change |
| Roadzen Inc. RDZNW | 225.0K | $42,750 | 0.01% | no change |
| Alpha Modus Hldgs Inc. AMOD | 9.9K | $41,974 | 0.01% | new |
| Aeon Biopharma Inc. AEON | 42.4K | $30,494 | 0.00% | no change |
| Southland Hldgs Inc. SLNDWS | 860.3K | $25,809 | 0.00% | no change |
| Blue Gold Ltd BGLWW | 175.0K | $21,000 | 0.00% | no change |
| SHF Holdings Inc. SHFS | 75.9K | $18,215 | 0.00% | no change |
| Blacksky Technology Inc. BKSYWS | 350.0K | $17,500 | 0.00% | no change |
| Tevogen Bio Hldgs Inc. TVGNW | 200.0K | $12,000 | 0.00% | no change |
| Zeo Energy Corp. ZEOWW | 250.0K | $10,000 | 0.00% | new |
| Livewire Group Inc. LVWRWS | 400.0K | $8,000 | 0.00% | new |
| Nvni Group Limited NVNIW | 200.0K | $6,000 | 0.00% | new |
| Katapult Holdings Inc. KPLT | 5.4K | $5,373 | 0.00% | no change |
| Cid Holdco Inc. DAICW | 444.5K | $4,445 | 0.00% | no change |
| Baird Med Invt Hldgs Ltd BDMDW | 100.0K | $4,000 | 0.00% | no change |
| Pagaya Technologies Ltd PGYWW | 48.7K | $2,433 | 0.00% | no change |
| Stardust PWR Inc. SDSTW | 16.7K | $2,167 | 0.00% | no change |
| Liminatus Pharma Inc. LIMNW | 50.0K | $2,000 | 0.00% | no change |
| Waldencast PLC WALDW | 33.3K | $1,667 | 0.00% | no change |
| XBP Europe Holdings Inc. | 24.8K | $1,487 | 0.00% | no change |
| Aspire Biopharma Hldgs Inc. ASBPW | 50.0K | $1,000 | 0.00% | no change |
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read more
Change is shares against its 13F for the quarter before; the 22 it sold out of are in the box above.Options it reported
| Company | Option | Shares under the options | Value of those shares |
|---|---|---|---|
| Compass Pathways PLC | Calls | 1.7M | $5.2 million |
| Erasca Inc. | Calls | 100.0K | $795,000 |
| Eledon Pharmaceuticals Inc. | Calls | 200.0K | $285,000 |
| Larimar Therapeutics Inc. | Calls | 728.6K | $145,720 |
| Compass Therapeutics Inc. | Calls | 303.8K | $106,330 |
5 option lines. A 13F lists calls and puts by the shares they cover and what those shares were worth at the quarter's end, not what the options cost; they are not counted in the holdings above.